|
Descripción
|
|
|---|---|
| The present invention relates to the use of neutrophil gelatinase-associated lipocalin (NGAL=LCN2=24p3) as a diagnostic tool for alelrgy and as a therapeutic method of treating, reducing, or ameliorating clinical manifestations of allergic disease. The invention includes measurement of NGAL levels in body fluids such as serum/plasma/saliva/blood and urin to determine sensitization state in allergic human and pet individuals. Moreover, it includes administering to the patient NGAL or lipocalin allergens in an amount effective to treat, reduce or ameliorate allergic disease. A siderophore can be co-administered with the NGAL or lipocalin allergen. The invention also relates to administering a siderophore-iron complex for allergen immunotherapy. | |
|
Internacional
|
Si |
|
Estado
|
Solicitada |
|
Referencia Patente Prioritaria
|
EP 14150965.3. |
|
En explotación
|
No |
|
Licenciatarios
|
|
|
Fecha solicitud
|
17/07/2013 |
|
Titulares aparte de la UPM
|
|